2026-04-30T15:06:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/264202025-12-18T13:00:01Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16968

00925njm 22002777a 4500 dc Laniece Delaunay, Charlotte author Martínez-Baz, Iván author Sève, Noémie author Domegan, Lisa author Mazagatos, Clara author Buda, Silke author Meijer, Adam author Kislaya, Irina author Pascu, Catalina author Carnahan, AnnaSara author Oroszi, Beatrix author Ilić, Maja author Maurel, Marine author Melo, Aryse author Sandonis-Martin, Virginia author Trobajo-Sanmartín, Camino author Enouf, Vincent author McKenna, Adele author Pérez-Gimeno, Gloria author Goerlitz, Luise author de Lange, Marit author Rodrigues, Ana Paula author Lazar, Mihaela author Latorre-Margalef, Neus author Túri, Gergő author Castilla, Jesús author Falchi, Alessandra author Bennett, Charlene author Gallardo, Virtudes author Dürrwald, Ralf author Eggink, Dirk author Guiomar, Raquel author Popescu, Rodica author Riess, Maximilian author Horváth, Judit Krisztina author Casado, Itziar author García, Mª Del Carmen author Hooiveld, Mariëtte author Machado, Ausenda author Bacci, Sabrina author Kaczmarek, Marlena author Kissling, Esther author European Primary Care Vaccine Effectiveness Group author 2024-03 Background: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. Results: Among adults, PS VE was 37% (95% CI: 24-47%) overall and 60% (95% CI: 44-72%), 43% (95% CI: 26-55%) and 29% (95% CI: 13-43%) < 90, 90-179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32-51%) overall and 56% (95% CI: 47-64%), 22% (95% CI: 2-38%) and 3% (95% CI: -78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification. Conclusion: Primary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity. Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; European Primary Care Vaccine Effectiveness Group. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. Euro Surveill. 2024 Mar;29(13):2300403. 10.2807/1560-7917.ES.2024.29.13.2300403 1560-7917 1025-496X Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin 38551095 https://hdl.handle.net/20.500.12105/26420 BA.1 BA.2 COVID-19 SARS-CoV-2 Test-negative design Vaccine effectiveness Symptomatic infection COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022